Ignite Creation Date:
2024-05-06 @ 3:55 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04802070
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2021-03-15
Brief Title:
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment
Sponsor:
Prof Franca Fagioli
Organization:
Azienda Ospedaliera Ospedale Infantile Regina Margherita SantAnna
Study Overview
Official Title:
A Phase I Study of Adoptive Immunotherapy With Cytokine-Induced Killer Cells in Relapsed and Non-resectable Sarcomas After Multimodal Treatment
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Monocentric phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer CIK
In the first part of the study Patients peripheral blood will be collected and CIK cell expansion and storage will occur at the Regina Margherita Childrens Hospital Cell Factory
In the second part of the study the Maximum Tolerated Dose MTD will be determined in order to find the Recommended Dose for Phase II RP2D
In the first part of the study Patients peripheral blood will be collected and CIK cell expansion and storage will occur at the Regina Margherita Childrens Hospital Cell Factory
In the second part of the study the Maximum Tolerated Dose MTD will be determined in order to find the Recommended Dose for Phase II RP2D
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None